Please ensure Javascript is enabled for purposes of website accessibility

Without a Coronavirus Vaccine Of Its Own, Is There Any Hope For CureVac Stock?

By Alex Carchidi - Jun 29, 2021 at 7:19AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Things are looking bleak right now, but they might improve with enough time.

When most of a company's eggs are in one basket, it's entirely reasonable to want to sell your shares if you find out there's a big hole in the bottom. 

Such is the case with CureVac (CVAC -5.16%) in light of its most recent coronavirus vaccine trial. The latest data readout from the trial was a total catastrophe, and the stock plummeted as a result. The company probably isn't finished, but investors should probably steer clear for the foreseeable future -- unless they're interested in taking a risk by bucking the trend, that is.

A group of four businesspeople express frustration while one talks on the phone and others look at laptops and papers.

Image source: Getty Images.

Why CureVac's first coronavirus vaccine project is dead

On June 16, CureVac dolefully reported that its massive phase 2 clinical trial had shown that its candidate was only 47% effective against coronaviral infections of any severity. In other words, the trial was a complete failure. Management blames the vaccine's ineffectiveness on the high number of viral variants that weren't around when it was being developed. While the data appear to support this conclusion -- only one of the vaccinated patients got sick with the original coronavirus strain -- it isn't the whole story. The company's analysis of the trial also indicated that people over age 60 probably didn't get much benefit from the jab.

More importantly, CureVac's competitors that are already selling their vaccines at scale don't suffer from any of the same issues. Products from Moderna and Pfizer appear to be effective against the viral variants, and they seem to work just fine for older people. Plus, both the Moderna and the Pfizer inoculations are based on mRNA technology, just like CureVac's candidate. So, it's probable that the nuances of the company's approach are responsible for the candidate's poor performance.

^SPX Chart

^SPX data by YCharts

There could be light at the end of the tunnel

As damaging as the vaccine failure was for investors, CureVac's stock isn't fated to keep falling. 

The company will shift its efforts to focus on its second-generation candidate being developed in conjunction with GlaxoSmithKline, which it hopes will be more effective against the circulating viral variants. In preclinical studies with rats, the jab appears to be effective against the viral variants that stymied CureVac's first attempt. Still, the newer project won't enter clinical trials until sometime in the third quarter, which puts its potential release well into 2022, assuming that it can continue to succeed where the other candidate failed.

In 2022, it's entirely possible that the demand for coronavirus vaccines will be much lower than it is currently. Alternatively, different viral variants could be more common, so the new candidate might have similar issues as before. Either way, CureVac will need to show that its jab will be effective in older people well in advance of it hitting the market to have a chance against the competition. And if one thing's certain, the company will have even more competition by then, so it'll be harder to win market share in such a crowded field.

Investors can take solace in two of the company's other projects, both of which are immunotherapies for cancer in phase 1 of clinical trials. One of the programs, CV8102, could eventually be used to treat several different malignancies, including squamous cell skin cancer, melanoma, and head and neck cancers. The other, BI1361849, is aimed at treating non-small cell lung cancer. Though it'll be quite some time before either of these drugs might be ready for regulatory approval, they could be the goldmines that the unprofitable company badly needs.

Contrarians beware

So, assuming that CureVac's stock has already priced in the coronavirus vaccine debacle, the coming months and years have a few potential catalysts on the calendar already. That means the stock could be an attractive purchase for investors willing to go against the market's recent pessimistic sentiment. 

Nonetheless, it's critical to keep CureVac's prospects in context. Whereas a month ago CureVac was a company potentially on the verge of coming out with an in-demand vaccine, it's now an early-stage biotech once again. There's no guarantee that its second-generation jab or its immuno-oncology projects will bear fruit, and the risks of investing are as high as ever.

At this point in time, there are definitely better places to invest.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool recommends GlaxoSmithKline and Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CureVac N.V. Stock Quote
CureVac N.V.
$12.50 (-5.16%) $0.68
Pfizer Inc. Stock Quote
Pfizer Inc.
$48.58 (-1.40%) $0.69
GSK Stock Quote
$34.25 (-0.17%) $0.06
Moderna, Inc. Stock Quote
Moderna, Inc.
$150.00 (-5.06%) $-8.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.